Asymptomatic microscopic haematuria and significant urinary tract disease
Bryan, Richard T.; Kockelbergh, Roger C.

DOI:
10.3233/BLC-199006
10.3233/BLC-199006

License:
Creative Commons: Attribution-NonCommercial (CC BY-NC)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Bryan, RT & Kockelbergh, RC 2019, 'Asymptomatic microscopic haematuria and significant urinary tract disease', Bladder Cancer, vol. 5, no. 2, pp. 115-117. https://doi.org/10.3233/BLC-199006, https://doi.org/10.3233/BLC-199006

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
Asymptomatic Microscopic Haematuria and Significant Urinary Tract Disease

Richard T. Bryan\textsuperscript{a,b} and Roger C. Kockelbergh\textsuperscript{b,c}
\textsuperscript{a}Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
\textsuperscript{b}Action Bladder Cancer UK, Tetbury, UK
\textsuperscript{c}Department of Urology, University Hospitals of Leicester NHS Trust, Leicester, UK

Asymptomatic microscopic haematuria (AMH), or non-visible haematuria (NVH), remains a conundrum to primary and secondary care alike; is it a sign of significant urinary tract disease, and does it require urgent investigation? The wide variation in international guidelines in defining who and when to refer adds further to this confusion [1].

In this edition of \textit{Bladder Cancer}, Ghandour et al present their evaluation of haematuria in a large public health care system in the USA [1] - Parkland Health and Hospital Systems, comprising a central hospital, 12 outpatient centres, 12 school-based clinics, and 5 mobile vans. They retrospectively studied a cohort of 11,422 patients \( \geq 18 \) years of age and with \( \geq 3 \) red blood cells (RBCs) per high power field (HPF) on urinalysis (UA) (some of whom had visible haematuria) in the outpatient clinic or emergency room between January 2015 and April 2018; they excluded patients with prior visits to any urology, nephrology, or oncology clinics prior to the date of the positive UA, patients with UA performed as an inpatient, and patients with previous renal transplantation. Their primary analysis excluded those patients initially diagnosed with a UTI. Their findings should be considered in the context of the American Urological Association (AUA) guidelines, defining microscopic haematuria as \( \geq 3 \) RBCs/HPF and strongly recommending evaluation with cross-sectional imaging using multiphasic computed tomography (CT) along with cystoscopic evaluation of all patients aged \( \geq 35 \) years without explained benign causes of the haematuria [2]. In the current study, over 83% of patients were aged \( \geq 35 \) years.

Only 11.4% of patients were referred to urology and, of those referred, only 35% received complete evaluation of haematuria (upper tract imaging and cystoscopy). With regard to referral patterns, older age, higher counts of RBCs/HPF on UA, hypertension, and repeated UA were all significant independent predictors of referral to a urologist, whereas female gender was a significant independent predictor of failure to refer (OR = 0.31, \( p < 0.001 \)). Of the 35% of referred patients who underwent complete evaluation, females, younger patients, black patients, and those patients with 3–19 RBCs/HPF (with the latter group representing 87% of the cohort, or 9,933 patients) were less likely to undergo complete evaluation.

Looking at the whole cohort, both referred and not referred, urinary tract disease was subsequently identified in 30% of patients; 3.7% of these patients were diagnosed with malignancy (\( n = 130 \), 1.1% of the whole cohort): 106 prostate cancers, 20 bladder cancers, 3 kidney cancers and one upper tract urothelial carcinoma (UTUC). All malignancies, except 53 prostate cancers, were diagnosed in the referred group, giving a cancer detection rate of 5.9% in those patients referred to urology, and a diagnosis of significant urinary tract disease in a further 72%. Focusing on the 24 cases of bladder cancer/kidney cancer/UTUC, we see that 17 (71%) were diagnosed in patients 35–65 years of age and 12 (50%) were diagnosed in patients with 3–19 RBCs/HPF on UA; 17 of the 21 urothelial cancers (81%) were high grade.

Secondary analyses by the authors in UTI patients with haematuria (\( n = 3241 \)) identified a further 13
cases of bladder cancer (0.4% of UTI patients with haematuria), 9 of which occurred in patients <65 years of age (69%) and 7 of which occurred in patients with 3–19 RBCs/HPF on UA (54%); 11 of these 13 cancers (85%) were high grade.

Aside from the key points made by the authors, we note the poor rate of referral, despite clear guidelines from the AUA [2]. This is further accentuated in female patients which, disappointingly, may demonstrate entrenched assumptions of UTI as the cause of haematuria (instead of significant other urinary tract diseases, including malignancy), thus leading to delayed diagnoses of malignancy [3]. Such delays may result in the stage migration observed in female bladder cancer patients compared to male patients [4], and worse survival [5]. And as the Parkland data also show, haematuria accompanying UTI does not exclude the possibility of malignancy.

Given the differences in referral guidelines between the UK and USA relating to age cut-offs for the investigation of AMH, and the similarities between the Parkland Health and Hospital System and the “average” UK National Health System (NHS) hospital and its network, the cancer detection rate of 5.9% in referred patients is comparable to 10.0–12.1% from UK data (13.8–18.9% for VH and 3.1–4.8% for NVH) [6, 7]. In line with the Parkland data presented here, Tan et al. observed that in the bladder cancers diagnosed following NVH, 59.4% were high-risk cancers, with 31.3% being muscle-invasive [7]. Importantly, in the Parkland cohort, a further 72% of referred patients were diagnosed with significant urinary tract disease ranging from hydronephrosis to urolithiasis (albeit considerably higher than observed in UK cohorts [6, 7]). Thus, urology referral identified significant disease (including malignancy) in the majority of patients, the vast majority of whom had been referred due to AMH and the majority of whom were <65 years old. This is a clear message for primary care practitioners and guideline committees.

Having established that AMH requires urological referral and complete evaluation, what is the urgency of referral and investigation? Bladder cancer patients already experience considerable delays in their diagnostic and treatment pathways [8]; whether such delays significantly influence outcomes remains complex and controversial (although the findings of pathway delays and worse outcomes for female patients remain consistent) [4]. In this regard, haematuria risk scores may permit us to bridge the gaps between primary care considerations, urological cancer concerns, and patient preferences [7]; as Ghandour et al. highlight, such risk scores exist and appear to have clear utility [9, 10]. In an era of stratified and personalised medicine, surely such risk scores must now become de rigeur [11]?

Perhaps in the near future, accessible, affordable, sensitive and specific non-invasive diagnostic biomarkers may solve this conundrum and transform haematuria referral decisions and subsequent treatment and surveillance pathways [11–15]?

DECLARATIONS/DISCLOSURES

RT Bryan has contributed to advisory boards for Olympus Medical Systems and Janssen.

ACKNOWLEDGMENTS

The authors have no acknowledgments.

FUNDING

The authors report no funding.

CONFlict OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

[1] Ghandour. Evaluation of hematuria in a large public health care system. Bladder Cancer. 2019. Ref Type: Journal (Full).
[2] Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Lev- eillee RJ, Messing EM, Miller SD, Peterson AC, Turk TM, Weitzel W. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188:2473-81.
[3] Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: Evidence from secondary analysis of an English primary care audit survey. BMJ Open. 2013;3.
[4] Bryan RT, Evans T, Dunn JA, Iqbal G, Bathers S, Collins SI, James ND, Catto JWF, Wallace DMA. A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. Eur Urol Focus. 2015;1:82-9.
[5] Kockelbergh R, Hounsome L, Mayer E. The Epidemiology of urological cancer 2001-2013. Journal of Clinical Urology. 2017;10:3-8.
[6] Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int. 2006;97:301-5.
[7] Tan WS, Feber A, Sarpong R, Khetrapal P, Rodney S, Jalil R, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson
A, Watson D, Cherian J, Williams N, Brew-Graves C, Kelly JD. Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. Eur Urol. 2018; 74:10-4.

[8] Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S. Delay and survival in bladder cancer. BJU Int. 2002;89:868-78.

[9] Loo RK, Lieberman SF, Slezak JM, Landa HM, Mariani AJ, Nicolaisen G, Aspera AM, Jacobsen SJ. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc. 2013;88:129-38.

[10] Tan WS, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser CD, Waisbrod S, Hermanns T, Sasieni P, Kelly JD. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. J Intern Med. 2019;285:436-45.

[11] Lotan Y. Re: Who Should be Investigated for Hematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. Eur Urol. 2018;74:15-6.

[12] Feber A, Dhami P, Dong L, de WP, Tan WS, Martinez-Fernandez M, Paul DS, Hynes-Allen A, Rezae S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng KK, Zeegers MP, Bryan RT, James ND, Paramio JM, Freeman A, Beck S, Kelly JD. UroMark—a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics. 2017:9:8.

[13] Ward DG, Bryan RT. Liquid biopsies for bladder cancer. Transl Androl Urol. 2017;6:331-5.

[14] Wald C. Diagnostics: A flow of information. Nature. 2017;551:S48-S50.

[15] Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, Silcock L, Whalley CM, Stockton JD, Beggs AD, Griffiths M, Abbotts B, Ijakipour H, Latheef FN, Robinson R, White AJ, James ND, Zeegers MP, Cheng KK, Bryan RT. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: A 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU Int. 2019.